Trials / Completed
CompletedNCT00607633
Candesartan and Candesartan/ Hydrochlorothiazide in the Treatment of Patients With Hypertension and LVH
Candesartan and Candesartan/ Hydrochlorothiazide in the Treatment of Patients With Essential Hypertension and a Concomitant Disease Left Ventricular Hypertrophy
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 686 (actual)
- Sponsor
- AstraZeneca · Industry
- Sex
- —
- Age
- —
- Healthy volunteers
- Not accepted
Summary
The CandLE study with at maximum daily dose of 32 mg candesartan or 16/12.5 mg candesartan/hydrochlorothiazide has the objective to evaluate under naturalistic conditions, i.e. under routine medical care conditions, the impact of the antihypertensive therapy with candesartan or candesartan/HCT on relevant medical parameters related to the left ventricular hypertrophy (LVH) as well as the efficacy and tolerability of candesartan or candesartan/HCT in subjects suffering from essential hypertension..
Conditions
Timeline
- Start date
- 2007-01-01
- Completion
- 2007-10-01
- First posted
- 2008-02-06
- Last updated
- 2008-02-06
Source: ClinicalTrials.gov record NCT00607633. Inclusion in this directory is not an endorsement.